CClinicalTrials.gg
CompletedNCT06462157Updated May 7, 2026

Group Compassionate Mind Training for Adults Experiencing the Menopause Transition

An interventional study of Compassionate Mind Training in Menopause, sponsored by University College, London. Completed at 1 site in United Kingdom. Open to female participants aged 40 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by University College, London · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
Female
01

Study summary

Menopause transition occurs naturally for women aged 45-55. In addition to the hormone changes, there are often changes in other areas of life including low mood, anxiety, 'brain fog' and embarrassment. Some people may not be eligible for or want to receive hormone replacement therapy, therefore psychological treatments for menopause have been investigated. There is growing evidence for the use of Compassionate Mind Training (CMT). CMT aims to reduce feelings of self-criticism and shame which are commonly reported by adults experiencing the menopause, by helping individuals to take better care of themselves, known as self-compassion. Findings show menopausal individuals who are more self-critical may be more vulnerable to difficulties during menopause. Therefore, CMT could help manage this. CMT improves self-compassion and reduces depressive symptoms, with group formats found to be more effective than individual or self-help. A previous study of online self-help CMT for the menopause received positive feedback for the therapy and people improved in several areas including self-compassion. Clearly, there could be benefits to offering CMT as a treatment for menopause. Given that group CMT is effective in other populations and groups are more economical and practical for the NHS, this study is interested in looking at the impact of group CMT on menopause.

This study aims to find out how practical and suitable group CMT is for improving the wellbeing of adults experiencing the menopause, and what their views are on the therapy and taking part in the study. To measure the aims, we will look at the ease of recruiting people to the study, whether they are happy to be randomly allocated to receive the therapy or not, whether they stay in the study, the number of completed questionnaires and feedback from participants. It will also look at whether there have been any changes in different domains e.g. anxiety and self-compassion. This will be done through a variety of quantitative and qualitative outcomes.

02

Conditions studied

  • Menopause
03

In context

Lead sponsor

University College, London is the lead sponsor of 632 studies on the registry; 145 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Adults (aged 40-60) who are biologically female
  • Women who are experiencing symptoms of the menopause or peri-menopause; which is naturally occurring. This is identified through the STRAW criteria. Individuals have to answer Yes on at least one of the STRAW screening questions to ensure women are in the perimenopause or menopausal period.
  • Substantial English verbal communication and comprehension skills
  • Capacity to consent
  • Confident in using video conferencing applications (MsTeams)
  • Willingness to take part in a post-intervention interview about their experience.
  • PHQ-9 score 5-19 (mild to moderate clinical cut offs)
  • GAD-7 score 5-15 (mild to moderate clinical cut offs)

Exclusion criteria

Exclusion Criteria:

  • People under the age of 40
  • People currently receiving any form of psychology intervention.
  • Transgender females who are biologically male
  • More than 5 years post menopause.
  • PHQ-9 score greater or equal to 20 (severe clinical cut off)
  • GAD-7 score greater or equal to 15 (severe clinical cut off)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Online CMT groups

    Online Compassionate Mind Training

    Other: Compassionate Mind Training

  • No intervention
    Control Group

    Treatment as usual

Interventions

  • OtherCompassionate Mind Training

    Participants will attend 6 x 90-minute online CMT sessions. CMT is delivered by combining taught information, exercises, and practices. It is effective, so the aim is to explore its use with menopausal women.

    Also known as: CMT

06

What researchers measure

Primary outcomes

  1. The Revised Women's Health Questionnaire

    Measures health-related quality of life by measuring perceptions of physical and emotional experiences of middle-aged women. All subscales are scored from yes, definitely (1) to no, not at all (4) with subscales scored with a scoring algorithm transforming each score to a 0-100 scale.

    Time frame: To be completed within one week before and within one week after the intervention

  2. 36-Item Short Form Survey

    Measures quality of life. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability.

    Time frame: To be completed within one week before and within one week after the intervention

  3. The Menopause Representations Questionnaire (MRQ)

    Measure to assess beliefs about menopause. It consists of 20 items, scored either no (0), uncertain (1) or yes (2). Higher scores indicate more beliefs about the menopause.

    Time frame: To be completed within one week before and within one week after the intervention

  4. Fears of Compassion Scale

    Measures fears of compassion. It has 38 items, scored either dont agree at all (0) to completely agree (4) on a Likert scale. There are three subscales, subscale items are summed, with higher scores indicating higher fears of compassion.

    Time frame: To be completed within one week before and within one week after the intervention

  5. Patient Health Questionnaire-9 (PHQ-9)

    Measures severity of depression. Score from 0-27, higher scores represent higher severity of symptoms of depression.

    Time frame: To be completed within one week before and within one week after the intervention

  6. General Anxiety Disorder-7 (GAD-7)

    Measures severity of anxiety. Score from 0-21, higher scores represent higher severity of symptoms of anxiety.

    Time frame: To be completed within one week before and within one week after the intervention

  7. The forms of Self Criticising/Attaching & Self-reassuring scale (FSCRS) SELF-REASSURING SCALE (FSCR

    Measures self criticism and the ability to self-reassure. It is a 22-item scale with the items making up three components; inadequate self, hatred self and self-reassure. Responses are given on a 5-point likert scale (0 = not at all lime me, to 4 = extremely like me). Higher scores indicate a greater sense of inadequacy (score 0-20), self-hate (score 0-16), and self-reassurance (score 0-20).

    Time frame: To be completed within one week before and within one week after the intervention

Secondary outcomes

  1. Post intervention interviews

    Qualitative data on experiences from the group

    Time frame: Within 5 weeks post intervention

07

Study locations

1 site
  • University College London
    London, County WC1E 6BT, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06462157
Lead sponsor
University College, London
Responsible party
Sponsor
First posted
Jun 17, 2024
Start date
Jun 20, 2024
Primary completion
Oct 23, 2025
Completion
Oct 23, 2025
Last update
May 7, 2026

Study contacts

Aimee Spector
principal investigator · UCL

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion